Glyburide nanosuspension: Influence of processing and formulation parameter on solubility and in vitro dissolution behavior

Main Article Content

Vinod Mokale


The aim of this study was to formulate and optimize Glyburide (GB) nanosuspension which is poorly waterâ€soluble antidiabetic drug with optimization of the dissolution property and bioavailability by reducing the particle at nano size.
The nanosuspension is prepared by Top down technique, i.e. high pressure homogenization. The formulation factors which
affects particle size including concentration of surfactant while processing parameters includes homogenization pressure and
homogenization cycle. After particle size reduction, we observe that there are increases in the surface energy which requires
adequate stabilization by surfactant. In this study, practically water insoluble GB was nanoground and surfactant was employed
for their stabilizing effect. Inâ€vitro dissolution study revealed that increase in release rate of GB from nanoparticles (NPS) as
compare to pure raw GB. Field Emission Scanning Electron Microscope (FEâ€SEM) study showed the spherical morphology
of NPS. Particles size distribution, zeta potential, and crystal form of the formulated nanosuspension were studied by using
particle size analyzer and Xâ€ray powder diffraction. The result showed that the drug dissolution rate in nanosuspension
formulation is depending upon crystal form, solubility, preparation procedure, and stabilizer employed.
Key words: Bioavailability, Glyburide, high pressure homogenization, lyophilization, nanosuspension


Download data is not yet available.

Article Details

How to Cite
Mokale, V. (2014). Glyburide nanosuspension: Influence of processing and formulation parameter on solubility and in vitro dissolution behavior. Asian Journal of Pharmaceutics (AJP), 7(3).


Dora CP, Singh SK, Kumar S, Datusalia AK, Deep A. Development

and characterization of nanoparticles of Glibenclamide by solvent

displacement method. Acta Pol Pharm 2010;67;283â€90.

Muller RH, Jacobs C, Kayser O. Nanosuspensions as particulate drug

formulations in therapy Rationale for development and what we can

expect for the future. Adv. Drug Deliv. Rev 2001;47:3â€19.

Davis SN, Granner DK. The pharmacological basis of therapeutics.

In: Hardman JG, Limbird LE, Gilman AG, editors. New York: McGrawâ€Hill;

p. 1679.

Kocbek P, Baumgartner S, Kristl J. Preparation and evaluation of

Nanosuspension for enhancing the dissolution of poorly soluble drugs.

Int J Pharm 2006;312:179â€86.

Tousif K, Mokale VJ. Nanosuspension: A novel approach for

enhancement of solubility and subsequent bioavailability. Inventi

Rapid:NDDS 2012:456 (4).

Naik JB, Mokale VJ. Formulation and evaluation of Repaglinide

nanoparticles as sustained release carriers. Int J Pharm Sci


Cerdeira AM, Mazzotti M, Gander B, Miconazole Nanosuspension:

Influence of formulation variables on particle size reduction and

physical stability. Int J Pharm 2010;396:2010â€8.

Singh SK, Srinivasan KK, Singare DS, Investigation of preparation

parameters of Nanosuspension by topâ€down media milling to improve

the dissolution of poorly waterâ€soluble Glyburide. Eur J Pharm Biopharm


Keck CM, Muller RH. Drug Nanocrystal of poorly soluble drugs

produced by high pressure homogenization. Eur J Pharm Biopharm


Lai F, Sinico C, Ennas G, Marongiu F, Marongiu G, Fadda AM. Diclofenac

Nanosuspension: Influence of preparation procedure and crystal form

on drug dissolution behavior. Int J. Pharm 2009;373:124â€32.

USPâ€NF 2007: The Official Compendia of Standards; The Dissolution

Procedure: Development and Validation. USP 30/NF 25; 1092.